Skip to main content

Table 1 Demographics and clinical characteristics of AIS patients with different prognoses

From: The relationship between systemic inflammation index, systemic immune-inflammatory index, and inflammatory prognostic index and 90-day outcomes in acute ischemic stroke patients treated with intravenous thrombolysis

Characteristics

Total (n = 190)

Good prognosis group (n = 157)

Poor prognosis group (n = 33)

P

Gender (male, n, %)

122 (64.2)

102 (65.0)

20 (60.6)

0.635

Age, mean (± SD)

70.389 ± 11.675

69.854 ± 11.201

72.939 ± 13.416

0.100

Vascular risk factors

    

Smoking, n (%)

    

 Yes

51 (26.8)

45 (28.7)

6 (18.2)

0.217

 No

139 (73.2)

112 (71.3)

27 (81.8)

Drinking, n (%)

    

 Yes

28 (14.7)

26 (16.6)

2 (6.1)

0.122

 No

162 (85.3)

131 (83.4)

31 (93.9)

Diabetes, n (%)

    

 Yes

56 (29.5)

46 (29.3)

10 (30.3)

0.908

 No

134 (70.5)

111 (70.7)

23 (69.7)

Hypertension, n (%)

    

 Yes

128 (67.4)

104 (66.2)

24 (72.7)

0.470

 No

62 (32.6)

53 (33.8)

9 (27.3)

CHD, n (%)

    

 Yes

33 (17.4)

25 (15.9)

8 (24.2)

0.252

 No

157 (82.6)

132 (84.1)

25 (75.8)

AF, n (%)

    

 Yes

13 (6.8)

11 (7.0)

2 (6.1)

0.845

 No

177 (93.2)

146 (93.0)

31 (93.9)

Medical history

    

Antiplatelet, n (%)

    

 Yes

44 (23.2)

37 (23.6)

7 (21.2)

0.771

 No

146 (76.8)

120 (76.4)

26 (78.8)

Statins, n (%)

    

 Yes

27 (14.2)

22 (14.0)

5 (15.2)

0.865

 No

163 (85.8)

135 (86.0)

28 (84.8)

Antihypertensive, n (%)

    

 Yes

117 (61.6)

95 (60.5)

22 (66.7)

0.509

 No

73 (38.4)

62 (39.5)

11 (33.3)

Hypoglycemic drug, n (%)

    

 Yes

52 (27.4)

42 (26.8)

10 (30.3)

0.677

 No

138 (72.6)

115 (73.2)

23 (69.7)

TOAST, n (%)

    

LAA

110 (57.9)

92 (58.6)

18 (54.5)

0.029

CE

25 (13.2)

16 (10.2)

9 (27.3)

SAO

47 (24.7)

43 (27.4)

4 (12.1)

Unclassified

8 (4.2)

6 (3.8)

2 (6.1)

OCSP, n (%)

    

TACI

34 (17.9)

25 (15.9)

9 (27.3)

0.142

PACI

63 (33.2)

52 (33.1)

11 (33.3)

LACI

69 (36.3)

62 (39.5)

7 (21.2)

POCI

24 (12.6)

18 (11.5)

6 (18.2)

Premorbid mRS, n (%)

    

 0

55 (28.9)

46 (29.3)

9 (27.3)

< 0.001

 1

105 (55.3)

86 (54.8)

19 (57.6)

 

 2

30 (15.8)

25 (15.9)

5 (15.2)

 

NIHSS, median [IQR]

4.000 [3.000,6.000]

3.000 [2.000,5.000]

7.000 [6.000,10.000]

< 0.001

SBP, mean (± SD)

153.000 ± 23.806

152.204 ± 23.473

156.788 ± 24.983

0.317

DBP, mean (± SD)

85.637 ± 14.868

84.701 ± 14.799

90.091 ± 14.381

0.056

Laboratory data

    

LDL, median[IQR]

2.750 [2.130,3.320]

2.750 [2.130,3.320]

2.810 [2.140,3.280]

0.875

HDL, median [IQR]

1.260 [1.080,1.500]

1.260 [1.100,1.500]

1.220 [1.060,1.390]

0.458

RBG, median [IQR]

6.180 [4.920,8.650]

6.050 [4.910,7.680]

7.420 [5.820,10.570]

0.024

Lymphocyte, median [IQR]

1.750 [1.260,2.350]

1.830 [1.330,2.410]

1.450 [0.930,1.770]

< 0.001

Monocyte, median [IQR]

0.500 [0.390,0.660]

0.510 [0.390,0.660]

0.460 [0.400,0.670]

0.946

Neutrophil, median [IQR]

4.420 [3.290,5.550]

4.320 [3.210,5.210]

4.970 [4.130,8.250]

0.001

Platelet, median [IQR]

186.000 [153.000,224.000]

188.000 [154.000,224.000]

177.000 [153.000,209.000]

0.372

MPV, median [IQR]

10.300 [9.700,11.200]

10.300 [9.700,11.200]

10.400 [9.700,11.200]

0.818

NLR, median [IQR]

2.368 [1.596,3.893]

2.159 [1.463,3.566]

3.509 [2.838,7.237]

< 0.001

CRP, median [IQR]

0.500 [0.500,1.740]

0.500 [0.500,1.500]

0.740 [0.500,4.260]

0.107

Albumin, median [IQR]

40.600 [37.700,42.900]

40.400 [37.700,42.600]

41.600 [37.700,43.500]

0.176

IPI, median [IQR]

0.047 [0.025,0.136]

0.043 [0.023,0.113]

0.109 [0.041,0.522]

< 0.001

SII, median [IQR]

451.644 [293.248,715.759]

413.571 [264.923,654.741]

636.842 [461.159,1088.124]

< 0.001

SIRI, median [IQR]

1.179 [0.732,2.036]

1.083 [0.707,1.844]

1.912 [1.298,3.726]

< 0.001